Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Donglu Zhao"'
Autor:
Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen, Jun Ma, Cheng-Shyong Chang, Eric Wai Choi Tse
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-26 (2023)
Abstract Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good cl
Externí odkaz:
https://doaj.org/article/910b3c2480ed4cd4b9096ea9dadac833
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 12 (2023)
A decision analytic model was constructed to assess the cost–effectiveness of obinutuzumab plus bendamustine followed by obinutuzumabmaintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O wa
Externí odkaz:
https://doaj.org/article/794a4f911ff04ae899b7c0edb878782c
Autor:
Weiping Liu, Donglu Zhao, Ting Liu, Ting Niu, Yongping Song, Wei Xu, Jie Jin, Qingqing Cai, Huiqiang Huang, Zhiming Li, Ming Hou, Huilai Zhang, Jianfeng Zhou, Jianda Hu, Jianzhen Shen, Yuankai Shi, Yu Yang, Liling Zhang, Weili Zhao, Kaiyang Ding, Lugui Qiu, Huo Tan, Zhihui Zhang, Lihong Liu, Jinghua Wang, Bing Xu, Hui Zhou, Guangxun Gao, Hongwei Xue, Ou Bai, Ru Feng, Xiaobing Huang, Haiyan Yang, Xiaojing Yan, Qingshu Zeng, Peng Liu, Wenyu Li, Min Mao, Hang Su, Xin Wang, Jingyan Xu, Daobin Zhou, Hongyu Zhang, Jun Ma, Zhixiang Shen, Jun Zhu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and s
Externí odkaz:
https://doaj.org/article/5c9000aa953646639a5acb21ddd9d292
Publikováno v:
Cancer Management and Research
Donglu Zhao, Qi Xing, Hang Song, Yan Zhao, Guiying Guo No. 4 Ward of Hematology Department, Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, Heilongjiang Province, People’s Republic of ChinaCorrespondence: Donglu ZhaoNo.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b39a93df03ca56f62e7fefe825487fb5
https://doi.org/10.2147/cmar.s274590
https://doi.org/10.2147/cmar.s274590
Autor:
Qingqing Cai, Dongfeng Zeng, Yu Fang, Yue Fei, Rong Liang, Haige Ye, Yun Liang, Xiuhua Sun, Michael Wang, Huiqiang Huang, Lugui Qiu, Tiejun Gong, Donglu Zhao, Yuxuan Che, Jinni Wang, Panpan Liu, Yi Wang, Tao Pan, Yao Lv, Panruo Jiang, Xuzhao Zhang, Jintai Deng, Shuhua Yi, Yizi He, Ling Xiao, Huijuan Lv, Jiangfang Feng, Huan Xie, Jiacheng Qian, Huilai Zhang, Hui Zhou
Background: Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma and therapeutic options of MCL are limited. We conducted a real-world, multicenter study enrolled 1261 MCL patients from nine medical centers in Ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd3e966e20c523bc437e9eee1f4f9d6e
https://doi.org/10.21203/rs.3.rs-1509422/v1
https://doi.org/10.21203/rs.3.rs-1509422/v1
Autor:
Weiping Liu, Jiangmei Liu, Yuqin Song, Xiaopei Wang, Lan Mi, Cai Cai, Donglu Zhao, Lijun Wang, Jun Ma, Jun Zhu
Publikováno v:
Aging. 14(7)
China is facing an aggravating disease burden of lymphoma. However, accurate information about lymphoma burden at the national and provincial levels is limited.The estimated number of disability-adjusted life years were 86,171.85 for Hodgkin lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f56eb1e81437bcdd90defa295bc4f36b
https://pubmed.ncbi.nlm.nih.gov/35398840
https://pubmed.ncbi.nlm.nih.gov/35398840
Autor:
Yongping Song, Ting Liu, Donglu Zhao, Xiaobing Huang, Wei Xu, Guangxun Gao, Haiyan Yang, Jun Zhu, Jinghua Wang, Wei-Li Zhao, Qingqing Cai, Min Mao, Zhihui Zhang, Qingshu Zeng, Hongwei Xue, Kaiyang Ding, Jingyan Xu, Hang Su, Yuankai Shi, Ting Niu, Liling Zhang, Peng Liu, Hongyu Zhang, Jianzhen Shen, Lihong Liu, Huiqiang Huang, Jianfeng Zhou, Xiaojing Yan, Ru Feng, Jie Jin, Jianda Hu, Huilai Zhang, Xin Wang, Jun Ma, Huo Tan, Lugui Qiu, Bing Xu, Yu Yang, Daobin Zhou, Hui Zhou, Zhi-Xiang Shen, Ou Bai, Weiping Liu, Wenyu Li, Zhi Ming Li, Ming Hou
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58fe4731b3498f051335b4853ed8a940
Autor:
Donglu Zhao, Jiangmei Liu, Weiping Liu, Cai Cai, Jun Ma, Zhu Jun, Yuqin Song, Xiaopei Wang, Lan Mi, Lijun Wang
Publikováno v:
Hematological Oncology. 39
Background: China is facing the aggravating disease burden of lymphoma. However, the accurate information about lymphoma burden at national and provincial levels is limited. Methods: Following the general analytical strategy used in Global Burden of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78444a3c67bb06fb6322982afc16a4ef
https://doi.org/10.1002/hon.194_2880
https://doi.org/10.1002/hon.194_2880
Autor:
Hun Lee, David Santos, Maria Badillo, Frederick B. Hagemeister, Jason R. Westin, Jorge E. Romaguera, Wendy Chen, Richard E. Champlin, Nicolaus A. Wagner-Bartak, Michael L. Wang, Laura T Lam, Donglu Zhao, Ken H. Young, Shaoying Li, Leo Zhang, L. Jeffrey Medeiros, Hui Zhang, Luis Fayad, Hubert H. Chuang, Felipe Samaniego, Maria Dela Rosa, Yasuhiro Oki, Alicia Addison, Francesco Turturro, Krystle Nomie
Publikováno v:
The Lancet Oncology. 17:48-56
Summary Background Ibrutinib is approved in the EU, USA, and other countries for patients with mantle cell lymphoma who received one previous therapy. In a previous phase 2 study with single-agent ibrutinib, the proportion of patients who achieved an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d9c509c88d1bd14001b314158748bff
https://doi.org/10.1016/s1470-2045(15)00438-6
https://doi.org/10.1016/s1470-2045(15)00438-6
Autor:
Qian, Jiang, Donglu, Zhao, Jie, Jin, Depei, Wu, Fanyi, Meng, Jianda, Hu, Bingcheng, Liu, Xin, DU, Ting, Liu, Yan, Li, Ming, Hou, Xiaopin, Han, Zhixiang, Shen, Jun, Ma
Publikováno v:
Chinese Journal of Hematology
To evaluate the early hematologic, cytogenetic and molecular responses in newly diagnosed patients with chronic myelogenous leukemia in chronic phase（CML-CP）and initially treated with a generic imatinib（Xinwei）, manufactured by Jiansu Hansoh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d138510cbfd154715ac4c0337f028db0
https://pubmed.ncbi.nlm.nih.gov/26462633
https://pubmed.ncbi.nlm.nih.gov/26462633